AgingResearch.NewsJoin free

Talengen Institute of Life Sciences, Shenzhen, P.R. China.

CompanyChina

Talengen Institute of Life Sciences, Shenzhen, P.R. China. develops one asset, in phase 1 (TP04HN106 in amyotrophic lateral sclerosis). Mostly other; based in China.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1

  • TP04HN106

    Investigational therapy for the treatment of amyotrophic lateral sclerosis

    Phase 1, Other, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Similar companies6

Intelligence